Literature DB >> 23900502

Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis.

Yasutaka Ishii1, Tamito Sasaki, Masahiro Serikawa, Tomoyuki Minami, Akihito Okazaki, Masanobu Yukutake, Takashi Ishigaki, Keiichi Kosaka, Teruo Mouri, Satoshi Yoshimi, Akinori Shimizu, Tomofumi Tsuboi, Kazuaki Chayama.   

Abstract

Cholangiocarcinoma (CCA) occurs frequently in primary sclerosing cholangitis (PSC). Cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1) induced by inflammation are believed to mediate prostaglandin E2 (PGE2) production thereby promoting carcinogenesis. Their expression in PSC-associated CCA tissues and non-neoplastic bile duct epithelial cells (BDECs) in PSC was investigated. COX-2 and mPGES-1 levels in 15 PSC patients (7 with CCA) were scored using immunohistochemical staining. The results were compared with those obtained in CCA tissues and non-neoplastic BDECs (controls) of 15 sporadic CCA patients. Non-neoplastic BDECs from large and small bile ducts were investigated separately. The mRNA expression levels of COX-2 and mPGES-1 in CCA tissues were analyzed by quantitative polymerase chain reaction. Ki-67 immunostaining was performed to evaluate cell proliferation. COX-2 was strongly expressed in PSC-associated CCA tissues and non-neoplastic BDECs in PSC. This expression was significantly upregulated in both compared with sporadic CCA tissues and non-neoplastic BDECs in sporadic CCA (both P<0.01). mPGES-1 was expressed at moderate to strong levels in PSC. Compared with controls, the expression was significantly higher in non-neoplastic small BDECs (P<0.01). COX-2 mRNA levels were significantly higher in PSC-associated tissues than in sporadic CCA tissues (P<0.01). Conversely, no differences were observed in mPGES-1 mRNA levels. Ki-67 labeling indices were higher in PSC-associated CCA tissues and non-neoplastic BDECs in PSC than in controls. In conclusion, COX-2 and mPGES-1 were highly expressed in PSC-associated CCA tissues and non-neoplastic BDECs in PSC, suggesting the involvement of COX-2 and mPGES-1 in cholangiocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23900502     DOI: 10.3892/ijo.2013.2038

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

Authors:  Runping Liu; Xiaojiaoyang Li; Xiaoyan Qiang; Lan Luo; Phillip B Hylemon; Zhenzhou Jiang; Luyong Zhang; Huiping Zhou
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

2.  Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities.

Authors:  Javier Angulo; Pedro Cuevas; Begoña Cuevas; Mohammad El Youssef; Argentina Fernández; Eduardo Martínez-Salamanca; Rocío González-Corrochano; Guillermo Giménez-Gallego
Journal:  J Transl Med       Date:  2015-02-01       Impact factor: 5.531

3.  Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.

Authors:  Guohe Lin; Yongcheng Liu; Shuhong Li; Yize Mao; Jun Wang; Zeyu Shuang; Jianlin Chen; Shengping Li
Journal:  Oncotarget       Date:  2016-08-09

4.  Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis.

Authors:  Huyen Thi La; Dao Bich Thi Tran; Hai Manh Tran; Linh Trong Nguyen
Journal:  J Immunol Res       Date:  2021-06-02       Impact factor: 4.818

Review 5.  Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers.

Authors:  Christian Mayr; Marlena Beyreis; Andrej Wagner; Martin Pichler; Daniel Neureiter; Tobias Kiesslich
Journal:  Biomed Res Int       Date:  2016-11-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.